CAR-T Meeting 2026 | Building alignment in CAR-T data collection using a Delphi survey
In this video, Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, briefly discusses a Delphi survey conducted to reach consensus among experts in the field of CAR T-cell therapy and build alignment in CAR-T data collection. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So one of the major challenges in the field is that we are collecting now with great success a lot of data from CAR-T treated patients, and the field is developing extensively and so we have registries not only in EBMT but also in other national registries, and people get so much excited about what they would like to collect. There are a lot of consensuses, but there’s a lot of different opinions...
So one of the major challenges in the field is that we are collecting now with great success a lot of data from CAR-T treated patients, and the field is developing extensively and so we have registries not only in EBMT but also in other national registries, and people get so much excited about what they would like to collect. There are a lot of consensuses, but there’s a lot of different opinions. And the challenge is to get these different opinions together and maybe form more consensus. And the Delphi process is actually made for that. In the Delphi process, we repetitively ask different experts in the field what they think should be collected and over time, you will see that more and more consensus is formed because people realize ‘oh maybe others are right and we should rather collect this than what I wanted to collect’ and this, whatever we present tomorrow, I think it’s a great next step toward harmonization of data collection and we will also try to get all the national registries on board to show their view on what we have collected.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Cofounder and shareholder: Gadeta Founders B.V.; Inventor on patents related to γδTCR/ligand and genetic engineering; Research funding: Novartis, Miltenyi Biotech, and Gadeta.
